Company Performance Metrics
- Cham Chetty: CEOPast Role: bioMerieux, Director
The company’s current products include an FDA approved HIV-1 assay (a Class III device), an FDA licensed HTLV-I/II assay for screening serum and plasma from blood donor, and cadaveric samples, which also has CE marking and Health Canada approval. In addition, three other products with CE marking including a homogeneous biochemiluminescence
based Flu A/B diagnosis test, a rapid influenza virus drug resistance test and an Oral fluid collection device. The company has two other HIV products in final development; a 4th Gen HIV-1/2/Ag test and an HIV Profile assay for the detection and estimation of antibody levels directed to different gene products of HIV-1 and HIV-2. The company also offers contract research, development and manufacturing for diagnostic test kits and critical biomaterials to third parties.
